Geron Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing imetelstat for blood cancers. The company’s disclosures cover RYTELO product revenue, operating results, financial guidance, clinical-development updates, and risks tied to oncology drug commercialization and hematology studies.
Geron’s SEC filings also record proxy governance matters, director elections, board committee assignments, executive compensation, and stockholder voting materials. Form 8-K reports document material events including furnished earnings releases and investor materials, amendments to secured debt arrangements, Nasdaq-listed common stock information, workforce restructuring and exit-cost disclosures, and board or executive officer changes.
Geron Corporation (GERN) filed a current report announcing it issued a press release with financial results for the quarter ended September 30, 2025 and recent business highlights. The press release is provided as Exhibit 99.1 and dated November 5, 2025.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and therefore is not subject to Section 18 liabilities and is not incorporated by reference into other filings.
Geron Corporation (GERN) reported an insider equity award. On 10/20/2025, the company granted its EVP, Chief Commercial Officer a stock option covering 3,000,000 shares of common stock at an exercise price of $1.27 per share, recorded at a grant price of $0 for the derivative security.
The option expires on 10/19/2035. Vesting is scheduled as follows: 375,000 shares vest on April 20, 2026; the remaining 2,625,000 shares vest in 42 equal monthly installments commencing April 20, 2026, contingent on continued service. The filing indicates direct ownership of the derivative securities following the grant.
Geron Corporation (GERN) executive Ahmed ElNawawi filed a Form 3 initial statement of beneficial ownership. The filing reports 10,000 shares of common stock beneficially owned directly.
ElNawawi serves as EVP, Chief Commercial Officer. The date of the event requiring the statement is 10/20/2025. Table II shows no derivative securities listed in this filing.
Geron Corporation announced leadership changes. On October 10, 2025, director Gaurav Aggarwal, M.D. resigned from the Board, effective immediately, citing professional obligations; the company stated his decision was not due to any disagreement on operations, policies, or practices. Also on October 10, V. Bryan Lawlis, Ph.D. informed the Board he will not stand for re‑election at the 2026 Annual Meeting and will serve until his term ends.
Effective October 15, 2025, Andrew J. Grethlein, Ph.D., Executive Vice President, Chief Operating Officer, and Jim Ziegler, Executive Vice President, Chief Commercial Officer, will depart. Each is eligible for severance benefits under existing employment agreements as described in the company’s April 8, 2025 proxy. To support transition, Dr. Grethlein entered a consulting agreement effective October 16, 2025 for up to 12 months at a specified hourly rate with a monthly hour cap. On October 13, 2025, the company issued a press release on four executive leadership transitions and appointments (Exhibit 99.1).
Geron Corp director Robert J. Spiegel received 5,702 shares of common stock as payment for his quarterly board and committee fees. The shares were issued on 09/30/2025 and priced at $1.37 per share, based on the closing price that day. After the issuance, Spiegel beneficially owns 188,546 shares. The Form 4 was signed by an attorney-in-fact on 10/01/2025. This disclosure reflects a routine non-derivative compensation issuance to a director and reports the resulting direct ownership level.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin jointly report beneficial ownership of 43,000,000 shares of Geron Corp common stock, equal to 6.75% of the outstanding class. The filing shows the reporting persons hold shared voting and shared dispositive power and report no sole voting or dispositive power.
The ownership percentage is calculated using 636,917,758 shares outstanding per Geron's 10-Q; the filers certify the shares were not acquired to change or influence control and include a joint filing statement assigning responsibility for future amendments.
Harout Semerjian, President & CEO and a director of Geron Corp (GERN), received stock option grants on 08/07/2025 totaling 11,000,000 options exercisable into common stock at an exercise price of $1.30 per share and expiring on 08/06/2035. The awards are direct beneficial ownership and were reported on a Form 4.
The grants vest in two schedules: one award of 7,000,000 options vests with 875,000 shares on February 7, 2026 and the remaining 6,125,000 in 42 equal monthly installments beginning February 7, 2026; a second award of 4,000,000 options vests with 1,000,000 shares on August 7, 2026 and the remaining 3,000,000 in 36 equal monthly installments beginning August 7, 2026, provided the optionee continues to provide services to the Company. These details describe the size, price, expiry and service‑conditioned vesting of the executive option grants.
Geron Corporation (GERN) reports that Harout Semerjian, who serves as President, CEO and a director, filed an initial Form 3 disclosing that he does not beneficially own any securities of the company. The filing was submitted through a power of attorney signature and lists the reporting address at the company.
Event: Geron Corporation (GERN) filed an 8-K reporting the appointment of Harout Semerjian as President, Chief Executive Officer and director, effective August 7, 2025.
- CEO appointment: Mr. Semerjian replaces Dawn C. Bir and will fill a Class I board vacancy through the 2027 annual meeting.
- Compensation: Annual base salary $800,000; annual performance target bonus 70% of base salary (prorated for 2025).
- Equity inducement: Grant of stock options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; exercise price = Nasdaq closing price on start/grant date.
- Vesting: 7,000,000 options: 12.5% at six months then monthly over 42 months; 4,000,000 options: 25% at one year then monthly over 36 months; full vest upon Change in Control.
- Severance: Covered Termination: prorated target bonus, lump-sum equal to 18 months base salary, COBRA for up to 18 months; vested options remain exercisable until earlier of two years post-termination or original expiration.
- Plan amendments: Amended and Restated Severance Plan effective August 1, 2025 adds a CEO payment equal to 150% of target bonus upon a qualifying Change of Control; 2018 Inducement Award Plan amended to add 11,000,000 shares for inducement grants.
- Exhibits: Employment Agreement (Exhibit 10.1), Amended Severance Plan (Exhibit 10.2), Amended 2018 Inducement Plan (Exhibit 10.3).